Positive Results for BaroPace Pacemaker Control Algorithm

Image credit: BaroPace

US medtech, BaroPace has confirmed positive results for its pacemaker control algorithm for treating heart failure with preserved ejection fraction (HFpEF) in its Phase I first-in-human trial.

Its  technology creates a real-time, bespoke, closed-loop therapy system for patients with HFpEF by wirelessly connecting a pacemaker, blood pressure cuff and the PressurePace algorithm.

Across 16 patients, the India-based multisite trial met both primary endpoints of quality of life and exercise tolerance, as well as its secondary endpoints of Six-Minute Walk Time and New York Heart Association (NYHA) Score compared to placebo, with no reported adverse events.

The results were recently presented at the Heart Rhythm Society Conference in Boston, a gathering of over 9,500 cardiac professionals.

“HFpEF is the most common form of heart failure worldwide and in most cases the result of treatment resistant hypertension,” said BaroPace CEO and Founder, Dr Michael Burnam in a press statement.

“PressurePace is a safe, very well tolerated, easy to implement personalized therapy for HFpEF, a real-time, closed-loop system that is active only when required.

“We are excited… to begin evaluation of PressurePace in resistant hypertension and its integration with a new cuffless blood pressure measurement device.”

Check out the press release via BaroPace for more information.